Patent ID: 8277806

Claim:
A method for reducing or inhibiting the formation of ascites fluid in a subject, the method consisting of: (a) providing a subject having malignant ascites, wherein the malignant ascites comprises tumor cells; and (b) administering to the subject intraperitoneally three or more doses of a pharmaceutical preparation containing trifunctional bispecific antibodies as the sole therapeutically active agents, wherein: (i) the trifunctional bispecific antibodies comprise: (1) a first binding arm that binds to a T cell in the subject via CD3; (2) a second binding arm that binds to EpCAM on a tumor cell associated with malignant ascites in the subject; (3) an Fc portion that binds to an Fc receptor-positive cell in the subject that comprises an Fcγ receptor I, an Fcγ receptor III, or a combination thereof; and (4) isotype combination rat-IgG2b/mouse-IgG2a; and (ii) the administering is in several increasing doses, with the amount of the trifunctional bispecific antibodies present in the second dose being higher than the amount of the trifunctional bispecific antibodies present in the first dose, and the amount of the trifunctional bispecific antibodies present in the third and any subsequent doses being higher than the amount of the trifunctional bispecific antibodies present in the second dose; thereby reducing or inhibiting the formation of ascites fluid in the subject.